Sangamo Therapeutics (SGMOQ) Interest & Investment Income (2011 - 2025)

Sangamo Therapeutics' Interest & Investment Income history runs 15 years deep, the most recent figure standing at $252000.0 for Q4 2025.

• On a quarterly basis, Interest & Investment Income fell 14.86% year-over-year to $252000.0 in Q4 2025; TTM through Dec 2025 was $1.3 million, a 13.95% decrease from a year earlier, with the FY2025 full-year figure at $1.3 million, down 13.95% from the prior year.
• Interest & Investment Income declined to $252000.0 in Q4 2025 per SGMOQ's latest filing, from $355000.0 in the prior quarter.
• Across five years, Interest & Investment Income topped out at $3.7 million in Q4 2022 and bottomed at $252000.0 in Q4 2025.
• The 5-year median for Interest & Investment Income is $1.1 million (2021), against an average of $1.4 million.
• Across the five-year window, Interest & Investment Income soared 145.38% in 2023 and sank 90.04% in 2024, its largest moves.
• Year by year, Interest & Investment Income stood at $2.3 million in 2021, then surged by 57.45% to $3.7 million in 2022, then slumped by 59.43% to $1.5 million in 2023, then tumbled by 80.16% to $296000.0 in 2024, then decreased by 14.86% to $252000.0 in 2025.
• Per Business Quant, the three latest SGMOQ Interest & Investment Income figures stand at $252000.0 (Q4 2025), $355000.0 (Q3 2025), and $386000.0 (Q2 2025).